Clinical Trial: Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973343) titled 'Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis' on Feb. 21.

Brief Summary: This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal cancer

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer Metastatic

Intervention: DRUG: Group A

Sintilimab 200mg Bevacizumab 7.5mg/kg Oxaliplatin 130mg/m2 Capecitabine 1250mg/m2

DRUG: Group B

Sintilimab 200mg Bevacizumab 7.5mg/kg Irinotecan 150mg/m2 C...